Fennec Pharmaceuticals (FENC) Accounts Payables (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Accounts Payables data on file, last reported at $4.6 million in Q4 2025.

• Quarterly Accounts Payables rose 43.01% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 43.01% YoY) and the FY2025 annual result came in at $4.6 million, up 43.01% from the prior year.
• Accounts Payables slipped to $4.6 million in Q4 2025, from $5.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.9 million in Q2 2025 to a low of $677000.0 in Q2 2021.
• A 5-year average of $3.2 million and a median of $3.0 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables plunged 75.43% — and 2022, when it surged 207.59%.
• Tracing FENC's Accounts Payables over 5 years: stood at $777000.0 in 2021, then surged by 207.59% to $2.4 million in 2022, then surged by 58.08% to $3.8 million in 2023, then declined by 14.21% to $3.2 million in 2024, then jumped by 43.01% to $4.6 million in 2025.
• The last three Accounts Payables figures came in at $4.6 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025), per Business Quant data.